Bausch + Lomb Corporation (BLCO) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Bausch + Lomb has acquired Elios Vision to enhance its glaucoma treatment capabilities with the innovative ELIOS procedure, which is minimally invasive and uses an excimer laser. This strategic move aims to integrate glaucoma treatment with cataract surgery, potentially transforming treatment standards for millions of patients globally.
For further insights into BLCO stock, check out TipRanks’ Stock Analysis page.